Biomarker for Gleason Score 7 Prostate Cancer Can Predict Aggressiveness
the Cancer Therapy Advisor take:
According to a new study published in the journal Clinical Cancer Research, researchers at the University of Texas MD Anderson Cancer Center in Houston, Texas, have identified a genetic variant near the KLK3 gene that can predict which patients with prostate cancer and a Gleason score of 7 will have a more aggressive type of the disease.
Prostate cancers associated with a Gleason score of 7 are an intermediate grade of cancer and account for about 30% to 40% of all prostate cancers. This biomarker could allow clinicians to determine whether patients will have a slow-growing or aggressive form of prostate cancer, allowing for better decision regarding treatment options.
For the study, the researchers analyzed the genetic makeup of 72 single nucleotide polymorphisms in 1,827 patients with prostate cancer. They then identified associations between the polymophisms and prostate cancer aggression. They found one polymorphism on the KLK3 gene on chromosome 19 that can predict whether or not a patient with prostate cancer and a Gleason score of 7 will have an aggressive form of the disease.
It can be sometimes difficult to determine the best treatment option for a patient with a Gleason score of 7 because the patient's cancer could be slow-growing or aggressive.
KLK3 gene predicts more aggressive type of the disease.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Immunotherapy in Glioblastoma: Peaks and Pits
- Opinion: Understanding the FDA's Take on Cannabidiol
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Polymorphism in HSD3B1 as a Potential Prognostic Biomarker in Prostate Cancer
- Opioid Use and Cancer
- OS and PFS End Points Not Met in Phase 3 Trial of Pembrolizumab in Advanced HCC
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Evidence of the Role of Circulating Insulin in Renal Cell Carcinoma Risk